Literature DB >> 20609898

Percutaneous vertebroplasty or kyphoplasty.

G C Anselmetti1, M Muto, Giuseppe Guglielmi, S Masala.   

Abstract

Percutaneous vertebral augmentation techniques performed with vertebroplasty or kyphoplasty are safe and effective for the treatment of osteoporotic vertebral compression fractures, primary or secondary spine tumors, and selected traumatic fractures. This article compares the procedures and outlines their advantages and disadvantages. It concludes that vertebroplasty should be performed in most cases, but kyphoplasty is preferable in selected cases. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20609898     DOI: 10.1016/j.rcl.2010.02.020

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  12 in total

1.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Authors:  Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

2.  [Current status of vertebroplasty and kyphoplasty in Germany: an analysis of surgical disciplines].

Authors:  A Krüger; J Hierholzer; M Bergmann; L Oberkircher; S Ruchholtz
Journal:  Unfallchirurg       Date:  2013-09       Impact factor: 1.000

3.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Authors:  Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

Review 4.  Current trends in mini-invasive management of spine metastases.

Authors:  Gianluigi Guarnieri; Roberto Izzo; Mario Muto
Journal:  Interv Neuroradiol       Date:  2015-05-11       Impact factor: 1.610

5.  Vertebral Body Compression Fractures and Bone Density: Automated Detection and Classification on CT Images.

Authors:  Joseph E Burns; Jianhua Yao; Ronald M Summers
Journal:  Radiology       Date:  2017-03-16       Impact factor: 11.105

6.  Evaluation of injectable silica-embedded nanohydroxyapatite bone substitute in a rat tibia defect model.

Authors:  Weiguo Xu; Cornelia Ganz; Ulf Weber; Martin Adam; Gerd Holzhüter; Daniel Wolter; Bernhard Frerich; Brigitte Vollmar; Thomas Gerber
Journal:  Int J Nanomedicine       Date:  2011-08-02

7.  Percutaneous vertebroplasty and interventional tumor removal for malignant vertebral compression fractures and/or spinal metastatic tumor with epidural involvement: a prospective pilot study.

Authors:  Yi-Feng Gu; Qing-Hua Tian; Yong-Dong Li; Chun-Gen Wu; Yan Su; Hong-Mei Song; Cheng-Jian He; Dong Chen
Journal:  J Pain Res       Date:  2017-01-20       Impact factor: 3.133

8.  Comparison of percutaneous vertebroplasty with and without interventional tumor removal for spinal metastatic tumor without epidural involvement.

Authors:  Yan Su; Zhong-Zhen Sun; Long-Xiang Shen; Jian Ding; Zheng-Yu Xu; Yi-Min Chai; Wen-Qi Song; Dong Chen; Chun-Gen Wu
Journal:  J Bone Oncol       Date:  2016-12-23       Impact factor: 4.072

9.  Traumatic burst fracture with spinal channel involvement augmentation with bioactive strontium-hydroxyapatite cement.

Authors:  S Masala; E Calabria; G Nano; R Iundusi; L Greco; R Di Trapano; U Tarantino; G Simonetti
Journal:  Case Rep Orthop       Date:  2013-08-01

10.  Comparative study on the biomechanics between improved PVP and traditional PKP in the treatment of vertebral peripheral wall damage-type OVCF.

Authors:  Tao Zhou; Hao Lin; Hongliang Wang; Xiaoqiang Chen; Fang He
Journal:  Exp Ther Med       Date:  2017-06-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.